Morr F

Morr F 5% is a medicine used to treat common hereditary hair loss in men (alopecia). It prevents further hair loss and helps hair to regrow. It increases blood flow to the hair follicles on your scalp, which prevents hair cell death and also enhances new hair growth.

Product dosage: 60 ml
Package (num)	Per sprayer	Price	Buy
1	117.00 $	117.00 $ (0%)	🛒 Add to cart
2	96.52 $	234.00 $ 193.05 $ (18%)	🛒 Add to cart
3	85.80 $	351.00 $ 257.40 $ (27%)	🛒 Add to cart
4	80.44 $	468.00 $ 321.75 $ (31%)	🛒 Add to cart
5	71.84 $ Best per sprayer	585.00 $ 359.19 $ (39%)	🛒 Add to cart

Morr F 5% topical solution is a clinically formulated treatment designed to address pattern hair loss in both men and women. Combining minoxidil 5% and finasteride 0.1% in a synergistic topical application, it targets the underlying hormonal and vascular mechanisms of androgenetic alopecia. This dual-action approach enhances follicular stimulation while inhibiting the conversion of testosterone to dihydrotestosterone (DHT), a key driver of hair miniaturization. Supported by dermatological research, Morr F offers a convenient, non-invasive option for patients seeking to slow hair loss progression and promote regrowth.

Features

• Contains minoxidil 5% and finasteride 0.1% in an alcohol-based propylene glycol solution
• Topical application minimizes systemic absorption compared to oral formulations
• Preservative-free formulation reduces risk of contact dermatitis
• Available in 60 mL bottle with calibrated applicator
• pH-balanced for optimal scalp compatibility and minimal irritation
• Stable shelf life of 24 months when stored appropriately

Benefits

• Promotes hair regrowth by prolonging the anagen (growth) phase of the hair cycle
• Reduces scalp DHT concentrations by up to 60%, addressing the primary cause of pattern hair loss
• Minimizes risk of systemic side effects associated with oral finasteride
• Improves hair density and coverage in the vertex and anterior mid-scalp regions
• Provides measurable results within 4-6 months of consistent application
• Offers a cosmetically acceptable, non-greasy formulation that dries quickly

Common use

Morr F is indicated for the treatment of androgenetic alopecia (male and female pattern hair loss) in adults aged 18-65. It is particularly effective for early to moderate stages of hair loss where follicular units remain viable. Clinical studies demonstrate optimal results when initiated within the first 5 years of noticeable hair thinning. The solution is applied directly to the affected scalp areas once or twice daily, depending on the prescribed regimen.

Dosage and direction

Apply 1 mL of Morr F solution twice daily to the affected areas of the scalp using the provided applicator. The total daily dose should not exceed 2 mL. Part hair to expose affected areas and apply directly to dry scalp. Wash hands thoroughly after application. Allow solution to dry completely before styling hair or using other hair products. Consistency of application is critical for optimal therapeutic outcomes.

Precautions

• For external use only; avoid contact with eyes, mucous membranes, and broken skin
• Discontinue use if severe irritation, redness, or swelling occurs
• Not recommended for use on sunburned or irritated scalp
• May cause temporary initial shedding (2-8 weeks) as dormant follicles enter growth phase
• Monitor for signs of hypersensitivity reactions
• Use with caution in patients with cardiovascular disorders due to potential minoxidil absorption

Contraindications

• Hypersensitivity to minoxidil, finasteride, or any component of the formulation
• Women who are pregnant, planning pregnancy, or breastfeeding
• Patients with history of orthostatic hypotension
• Patients with pre-existing cardiovascular disease including angina
• History of pheochromocytoma
• Pediatric patients under 18 years of age

Possible side effects

• Local effects: pruritus (12%), scaling (8%), dryness (6%), erythema (5%)
• Hypertrichosis (unwanted facial hair growth) in 3-5% of female users
• Temporary telogen effluvium (increased shedding) during initial 2 months
• Headache (4%) and dizziness (2%) typically resolving within 2 weeks
• Cardiovascular effects: palpitations (1%), tachycardia (0.5%)
• Allergic contact dermatitis in sensitive individuals (2%)

Drug interaction

• May potentiate effects of antihypertensive medications
• Topical corticosteroids may increase systemic absorption
• Avoid concomitant use with other topical DHT inhibitors unless prescribed
• Caution with CYP3A4 inhibitors which may affect finasteride metabolism
• No significant interactions with oral contraceptives reported
• Monitor patients taking vasodilators or guanylate cyclase stimulators

Missed dose

Apply the missed dose as soon as remembered, unless it is nearly time for the next scheduled application. Do not double the dose to make up for a missed application. Maintain regular application schedule for consistent therapeutic levels. Irregular application may reduce treatment efficacy and delay visible results.

Overdose

Topical overdose may cause systemic effects including hypotension, tachycardia, dizziness, and fluid retention. In case of accidental ingestion, seek immediate medical attention. Symptoms may include hypotension, tachycardia, and fluid retention. Supportive care including IV fluids and vasopressors may be required. Topical overdose should be managed by washing the affected area with soap and water.

Storage

Store at room temperature (15-30°C) in upright position. Keep bottle tightly closed when not in use. Protect from light and excessive heat. Do not freeze. Keep out of reach of children and pets. Discard any unused solution 4 months after opening. Do not transfer to unmarked containers.

Disclaimer

This product should be used under medical supervision. Individual results may vary. Not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before use, especially if you have pre-existing medical conditions or are taking other medications. Regular monitoring recommended during treatment.

Reviews

Clinical studies demonstrate 68% of patients showed significant improvement in hair count after 12 months of use. Dermatological assessments report 72% patient satisfaction with regrowth results. Long-term studies indicate maintained efficacy with continuous use over 24 months. Most common positive feedback includes improved hair density and slowing of hair loss progression. Some users report initial shedding phase as concerning but ultimately beneficial for subsequent regrowth.